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https://doi.org/10.1186/s12878-019-0139-2RESEARCH ARTICLE Open AccessResponse to Imatinib therapy is inferior
for e13a2 BCR-ABL1 transcript type in
comparison to e14a2 transcript type in
chronic myeloid leukaemia
Graeme Greenfield1* , Ross McMullan2, Nuala Robson2, Julie McGimpsey2, Mark Catherwood2 and
Mary Frances McMullin3Abstract
Background: The BCR-ABL1 fusion gene underlying the pathogenesis of CML can arise from a variety of breakpoints.
The e13a2 and e14a2 transcripts formed by breakpoints occurring around exon 13 and exon 14 of the BCR gene
respectively are the most common.
Methods: We undertook a retrospective audit using local laboratory database and electronic patient care records of
69 CML patients with an e13a2 or e14a2 transcript type identified in our regional population.
Results: The e13a2 group was on average significantly younger (45.0 years v 54.5 years), had a higher average white
cell count (189.8 × 109/l v 92.40 × 109/l) and lower platelet count (308 × 109/l v 644 × 109/l) in comparison to the e14a2
group suggesting that these are distinct biological entities. Over an average follow-up of 33.8 months and 27.2 months
for the e13a2 and e14a2 groups we observed an inferior molecular response to imatinib in the e13a2 group. A
significantly lower number of patients in the e13a2 arm met European Leukemia Net criteria for optimal response at
12months therapy (17.64% v 50.0%) and were slower to obtain deep molecular responses MR4 or MR4.5.
Conclusion: Patients with an e13a2 transcript demonstrate an inferior molecular response to imatinib in our regional
population.
Keywords: Chronic myeloid Leukaemia, Treatment free remission, BCR-ABL, e13a2 transcript, e14a2 transcriptBackground
Chronic myeloid leukaemia (CML) is characterised in
virtually all cases by the presence of a translocation be-
tween chromosomes 9 and 22 resulting in the formation
of the Philadelphia chromosome and a BCR-ABL1 fusion
protein [1–4]. This fusion results in the formation of a
constitutively active tyrosine kinase driving proliferation
of the myeloid lineage producing the disease phenotype
[5]. Diagnosis of CML is based on characteristic blood
findings co-existent with the presence of the Philadel-
phia chromosome or detection of BCR-ABL1 fusion gene© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
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1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, 97
Lisburn Rd, Belfast BT9 7NN, UK
Full list of author information is available at the end of the articleby polymerase chain reaction (PCR) or fluorescent in
situ hybridisation (FISH) [6].
Within the last 20 years, the development of specific
tyrosine kinase inhibitors (TKIs) targeting the
BCR-ABL1 fusion protein has revolutionised treatment
of the disease producing deep and sustained haemato-
logical and molecular responses [7, 8]. Imatinib is the
first generation of these TKIs and is the most fre-
quently used TKI as first line therapy in our setting.
Treatment free remissions following a sustained
period of imatinib therapy are now regularly reported
[9]. However, other patients respond less well to
imatinib therapy. In some cases, there is a failure to
obtain an adequate molecular response, progression of
disease to accelerated or blast phase or loss of
previously obtained molecular responses. This canle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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mutation in the genomic sequence encoding the
BCR-ABL1 transcript in some instances [10].
It is well recognised that there is variation in the
breakpoints that can occur to allow formation of
BCR-ABL1 fusion transcript [11]. In the vast majority of
cases this results in the formation of 210 kDa tyrosine
kinase (p210) with a smaller number producing a 190
kDa or 230 kDa product. The p210 BCR-ABL1 may be
encoded by a number of different transcripts. The most
common of these are e13a2 (also notated b2a2) and
e14a2 (also notated b3a2) accounting for greater than
95% of the CML population [11]. The e13a2 is formed
from a breakpoint at the 5′ aspect of the BCR gene
around exon 13 fused to exon 2 of the ABL1 gene. The
e14a2 results from a breakpoint in the 3′ aspect of the
BCR gene around exon 14 again fused to exon 2 of the
ABL gene. This results in a difference of 75 base pairs in
the hybrid mRNA between the two sequences and there-
fore a difference of 25 amino acids in the resulting
BCR-ABL1 fusion protein [12]. Alternative splicing
mechanisms mean that in patients with the e14a2
transcript, either the e13a2 or e14a2 may be expressed
from the one clone [13].
The relevant prognostic value of the underlying tran-
script type was evaluated in the pre TKI era but without
conclusive evidence of significant difference established
[12]. One study suggested that the duration of chronic
phase and length of time to progression to blast disease
was much shorter in the e14a2 group in comparison to
the e13a2 group [14]. Other studies failed to substan-
tiate this finding [15]. In the TKI era a number of
studies have evaluated the prognostic value of under-
lying transcript type. A recent meta-analysis was
suggestive of an inferior response in the e13a2 group
[16]. There are also recent reports of a difference in
the maintenance of treatment free remission
dependent on transcript type [17].
On the basis of these findings, we set out to establish
if the underlying transcript type was relevant for progno-
sis in our regional population for patients treated with
imatinib first line with a focus on achievement of a deep
molecular response.
Methods
Our laboratory database of all positive diagnostic
BCR-ABL1 transcripts within the Northern Ireland
region from 14/11/2011 was reviewed. Patients were
excluded from further analysis if the diagnosis was not
chronic myeloid leukaemia, if less than three months
had passed since diagnosis or if the transcript type was
not known. A retrospective audit of therapy and clinical
outcomes was then undertaken for seventy-four patients
(n = 74). Regional electronic patient records and locallaboratory database were used to obtain data. Exclusions
from further analysis were as follows; One patient with
an atypical transcript type, three patients as were not
initially commenced on imatinib therapy and one patient
who presented in blast phase of disease as per WHO cri-
teria. This left sixty-nine patients for analysis (n = 69).
Real-time quantitative PCR (RQ-PCR) was performed
using RNA extracted from Peripheral blood for monitor-
ing BCR-ABL1 transcript levels reported on the
International Scale (IS) [18]. The IS conversion factor
was derived from a sample exchange scheme performed
by Professor Nick Cross (Wessex Regional Genetics
Laboratory). RT-PCR was performed to determine
transcript type as previously described [19].
Statistical analysis was performed using Microsoft
Excel Software. Unpaired, two tailed t test was used to
determine significance of quantitative data whilst
Chi-square test of fit was used for assessment of qualita-
tive results. A multivariate regression analysis was per-
formed using all variables available for assessment.
Binary variables (transcript type, gender and meeting
optimal criteria) were coded as 0 and 1 for this analysis.
P values less than 0.05 were considered statistically sig-
nificant. Kaplan-Meier analysis was undertaken to deter-
mine overall survival, event free survival and probability
of maintaining MMR. A log rank test was used to gener-
ate p values for Kaplan-Meier curves.
Results
Baseline demographics
A total of sixty-nine patients were identified as suitable
for inclusion in this retrospective analysis. The baseline
demographics are presented in Table 1 with the e14a2
transcript more common. The e13a2 group was signifi-
cantly younger on average than the e14a2 group. There
was also a significantly higher white cell count (WCC)
and lower platelet count in the e13a2 group. Dual
expressers have been reported previously, we did not
identify any in this cohort.
Effect of transcript type on molecular response
We evaluated the molecular response at 3months (n = 56
pts), 6months (n = 51pts) and 12months (n = 47 pts).
BCR-ABL1 transcript levels within 1 calendar month
either side of time points were deemed acceptable for
inclusion. These levels were then compared against
the European Leukaemia Net (ELN) criteria for
optimal response at each time point [20].
Figure 1a demonstrates the average BCR-ABL1
transcript levels detected at each time point in year 1 for
each group. As is evident there is no significant
difference between the two groups at any time point. At
3 months, average BCR-ABL1 levels were 18.93% in the
e13a2 group and 18.08% in the e14a2 group. At 6
Table 1 A table showing the baseline demographics and initial
treatment for each group
e13a2 e14a2 p value
Number
% 29% 71.0% n/a
Exact 20 49
Age (years)
Mean 45.0 54.57 0.043
Median 46.0 59.0
Range 4–81 5–80
Sex
Male 75.0% 55.1% 0.125
Female 25.0% 44.9%
Follow-up (months)
Mean 33.85 27.24 0.192
Median 37.5 23
Range 1–70 3–76
Haemoglobin (g/l)
Mean 113.5 121.3 0.134
Range 86–148 64–158
White Cell Count
(×109/l) 189.80 92.40 0.0002
Mean 49.1–563 4.86–292
Range
Platelets (×109/l)
Mean 308 644 0.001
Range 93–1058 178–2507
EUTOS SCORE
Number available 15 42 0.685
Average Score 35.93 39.66
% High Risk 5.0% 6.1%
BCR-ABL1 PCR level
Number available 17 42 0.354
Mean 58.64% 71.0%
Range 25.6–112 8.1–344
Initial Treatment
Imatinib 400 mg/day 90% 93.9% n/a
Imatinib 300 mg/day 5% 0%
Imatinib 200 mg/day 5% 6.1%
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months 2.71 and 5.31% respectively. When the groups
were compared against the ELN criteria, at 3 months
and 6months there was a higher percentage of patients
in the e14a2 group meeting optimal response criteria. By
12months this had reached statistical significance with
fewer patients in the e13a2 group (17.64%) meeting ELNcriteria for optimal response in comparison to the e14a2
group (50.0%). This is demonstrated in Fig. 1b. This was
despite the non-significant difference observed in the
quantitative assessment of BCR-ABL1 transcript levels.
When patients who had undergone a change of TKI
therapy to second line therapy prior to 12months were
excluded from the analysis this statistical significance
remained with 21.2% of e13a2 patients meeting criteria
compared with 59.1% of e14a2 patients. Again there was
no significant difference observed in the quantitative
BCR-ABL1 transcript level when changers prior to 12
months were excluded (e13a2: 1.75%, e14a2: 1.64%).
Obtaining a major molecular response (MMR) is a pri-
mary objective in the therapy of CML within 12 months.
This is defined as a BCR-ABL1 transcript level less than
0.1% on the International Scale by ELN [20]. The
number of patients obtaining a MMR at any stage dur-
ing follow-up was assessed for both groups. The number
of patients obtaining MMR was greater in the e14a2 arm
for all patients (e13a2:60.0%, e14a2:63.2%), when pa-
tients undergoing change of therapy prior to obtaining
MMR were excluded (e13a2: 30.0%, e14a2:48.9%), and in
patients with greater than 12months of follow-up avail-
able (e13a2: 66.6%, e14a2:71.7%). However, none of these
differences reached statistical significance. This is dem-
onstrated in Fig. 2a. When the time to obtain MMR was
evaluated there was a trend towards earlier achievement
of MMR in the e14a2 group for all patients and exclud-
ing changers which again did not reach significance
(e13a2: 16.75 months and 11.5 months, e14a2: 11.80
months and 9.58 months). We then examined deeper
molecular responses. Achievement of MR4 (BCR-ABL1
< 0.01%) is crucial for the purposes of attempting
treatment free strategies. We evaluated the number of
patients obtaining levels less than 0.01% and found no
significant difference (e13a2: 40.0%, e14a2: 51.0%) be-
tween the two groups. However, there was a signifi-
cant improvement in time to achieve this seen in the
e14a2 group (e13a2: 24.5 months, e14a2: 15.6 months).
The results were similar for achieving MR4.5 with
BCR-ABL1 < 0.0032% however, the difference between
the two groups was marginally outside the level of
significance for time to achievement (p = 0.05). This is
shown in Fig. 2b. Figure 2c shows the cumulative in-
cidence of obtaining MMR and MR4.5 by transcript
type using 1-KM methodology. This demonstrates a
superior response for e14a2 transcripts which was sig-
nificant (p < 0.05) by Wilcoxon-Gehan methodology
and borderline for significance by log rank test (MMR
p = 0.10 and MR4.5 p = 0.07).
Loss of MMR is suggestive of treatment failure or dis-
ease progression but could represent poor compliance
with treatment. We defined loss of MMR as a sustained
increase above 0.1% transcript level or a significant
Fig. 1 a) The trend of quantitative BCR-ABL1 transcript levels by PCR over initial 12months of therapy by transcript type. b) The number of patients
meeting optimal ELN criteria by transcript type at each timepoint in year 1. EXC CHANGER = excludes patients changing TKI therapy prior to 12
months * = p value < 0.05
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evident between the two groups on comparison of the
percentage of patients losing MMR having previously
achieved it at any stage. (e13a2: 25.0%, e14a2: 22.5%).
Fig. 2d demonstrates there was no difference in the
probability of maintaining MMR for each transcript.
(p = 0.08). In 70% of cases of loss of MMR this was a
transient phenomenon.
A multivariate regression analysis was then undertaken
to establish if other variables were significant in obtain-
ing an optimal ELN criteria response of less than 0.1% at
12 months. Independent variables included in this ana-
lysis were transcript type, age, gender, EUTOS score at
diagnosis, BCR-ABL1 level at baseline, baseline
haemoglobin, baseline white cell count and baseline
platelet count. Patients without a 12 month
BCR-ABL1 result were excluded. As not all variables
were available for every patient, four multivariate ana-
lyses were then run to include patients with all vari-
ables (n = 29), patients with all variables excluding
EUTOS score (n = 39), patients with all variables
excluding BCR-ABL1 level (n = 35) and patients withall variables excluding EUTOS and BCR-ABL1 levels.
The significance of transcript type in determining op-
timal response at 12 months was lost in each of these
analyses. No other variables were consistently signifi-
cant across the four analyses.The effect of transcript type on therapy
The local laboratory system does not routinely release
the transcript type. Therefore, treating physicians across
the region are effectively blinded to this information
when making decisions to change therapy. We first
assessed the number of patients in each group receiving
a change of TKI therapy for all reasons (treatment fail-
ure, intolerance or unacceptable toxicity and patient
choice). There was no significant difference between the
number of patients in either group moving to second
line therapy (e13a2: 45%, e14a2: 40.8%) or significant
difference between the average time to switch (e13a2:
11 months, e14a2: 8.85 months). When we examined
those switching on account of treatment failure only, the
results were similar for numbers (e13a2 40%, e14a2:
Fig. 2 a) A chart showing the number of patients obtaining a MMR (BCR-ABL1 < 0.1%) by transcript type for all patients, excluding patients with
change of TKI therapy prior to milestone and for patients with greater than 12 months follow-up. b) Time to achievement of MMR
(BCR-ABL1 < 0.1%), MR4 (BCR-ABL1 < 0.01%) and MR4.5 (BCR-ABL1 < 0.0032%) by transcript group. * = p < 0.05. c) The cumulative incidence of
obtaining MMR and MR4.5 are demonstrated using a 1-KM method. d) Probability of maintaining MMR once achieved over time of
follow-up by transcript type, calculated using Kaplan Meier methodology. p = 0.08 using log rank test
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10.75 months). Fig. 3 demonstrates this.
Clinical outcomes by transcript type
Finally, we examined the clinical outcomes by transcript
type. Figure 4 shows the overall survival (OS) and event
free survival of both groups (EFS) showing no significant
difference between the two groups. During our
follow-up we observed two transformations to blast
crisis both within the e14a2 group. We also excluded
one patient from analysis at the outset presenting
with blast crisis by WHO criteria who was also an
e14a2 transcript. Four deaths during follow-up were
observed. Causes of death were documented as acute
liver failure from imatinib therapy at 1 monthfollow-up, infective complications at 22 months, con-
gestive cardiac failure at 26 months and intracranial
haemorrhage secondary to blast crisis at 25 months.
Allogeneic haematopoietic stem cell transplantation
(HSCT) was undertaken in three patients, two post
blast crisis and one for progressive disease not
responding adequately to TKI therapy. All patients
undergoing HSCT had e14a2 transcripts. Only 1 case
of a mutation in the BCR-ABL1 kinase domain was
detected in our population. This patient went on to
blast crisis.
Only two patients had stopped TKI therapy at the ces-
sation of follow-up. Neither of these were as a result of
elective stopping on account of meeting treatment cessa-
tion guidelines. Therefore, we are unable to comment
Fig. 3 A bar chart showing the number of patients changing TKI by transcript type for all reasons and as a result of treatment failure.
Superimposed on this is a line chart showing time to change for each transcript type for all reasons and for treatment failure
Greenfield et al. BMC Hematology            (2019) 19:7 Page 6 of 9on the impact of transcript type on maintenance of
treatment free remission.
Discussion
The role of front line imatinib therapy has been well
established in the treatment of CML, Now patients with
CML can expect an overall survival which is
approaching that of the general population [21]. There-
fore the goal of therapy in CML is shifting at the outset.
Particularly in the younger patient, the aim is to achieveFig. 4 Graphs showing Kaplan-Meier analysis of overall and event free surv
absence of death, blast crisis, failure of therapy requiring change or loss ofa early and sustained deep molecular response. This
opens the possibility of treatment free remission.
European Society of Medical Oncology (ESMO) guide-
lines have defined criteria allowing physicians and pa-
tients to consider treatment withdrawal if response to
initial therapy is deemed adequate. These guidelines
are strict, requiring sustained therapy for a minimum of
5 years, having achieving MR4.5 (BCR-ABL1IS < 0.0032%),
sustained MR4 (BCR-ABL1IS < 0.01%) for over 2 years and
optimal response on first line therapy in patients with aival by transcript type. Event free survival defined as survival in the
MMR. Intolerance of therapy was not included
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transcript type [6]. Although the withdrawal of treatment
is not going to be the favoured option for all patients, the
range of second generation and beyond TKIs mean that as
physicians the decisions regarding initial therapy will im-
pact on patients options further down the line if there are
slight differences in efficacy in particular circumstances.
Therefore, obtaining an optimal response with first line
therapy is of critical importance to patients wishing to
regain the normality of treatment free life.
The e14a2 transcript type was more common in our
population. The majority of other studies also report this
although there may be some differences across varying
ethnicities [16]. Our laboratory did not detect any
co-expressers. The prevalence of these co-expressers has
been between 0 and 20% in other cohorts therefore this
may just be on the basis of the limited patient numbers
in our study [16]. Our findings of a differential in WCC
and platelet count point to a biological difference be-
tween these two groups. There is a bias towards throm-
bopoiesis in cells containing e14a2 and a bias towards
leucopoiesis in those with e13a2. The difference in plate-
let count has been regularly reported previously in the
majority or trials with the difference in white cell count
also reported but less frequently [16, 22, 23]. There is a
75 base pair difference between the two transcripts
resulting from the differing breakpoints. This results in a
difference of 25 amino acid residues in the resulting fu-
sion tyrosine kinase. Whether this difference in prolifer-
ative capacity is a direct result of the action of this
tyrosine kinase mediating differences in downstream sig-
nal transduction pathways has not been demonstrated,
however the secondary structure is predicted to differ
between the two proteins [24]. It is conceivable that this
structural difference may impact on TKI effectiveness.
Molecular responses evaluated by RT-PCR form a crit-
ical component of follow-up for CML, and directions on
the continuation or alteration of specific therapies are
based upon these. At low levels of disease burden, FISH
and cytogenetics are insufficiently sensitive to detect
CML clonal cells. We have not examined whether ampli-
fication of either allele is identical by RT-PCR in our in-
dividual setting. However, given that clinical decision
making is based upon the IS BCR-ABL1 levels derived
from these RT-PCR levels this does not impact on the
validity of the study. When molecular responses were
examined, we identified a trend towards improved re-
sponses in the e14a2 group reaching statistical signifi-
cance for the number of patients meeting optimal
response by ELN criteria at 12 months and time to
achieve a deep molecular response MR4. There was also
a trend towards improved responses for achieving opti-
mal response at 3 and 6months, achieving MMR and
MR4.5 at an earlier stage and a lower number of patientsrequiring therapy change due to treatment failure in the
e14a2 group. Therefore, our results are consistent with
improved molecular responses to front line imatinib
therapy in a real world population of unselected individ-
uals with CML for patients with the e14a2 group in
comparison to the e13a2 group. Our study is limited by
relatively small numbers but these results are largely in
keeping with previous studies showing that patients with
e14a2 obtain deeper, more sustained responses, faster
than the e13a2 patients [16, 22, 23]. In our study and
others, this does not impact on clinical outcomes [25]. A
recent study comparing the expression of the BCR-ABL1
transcript to the level of genomic BCR-ABL1 DNA
present in cells has suggested that although the expres-
sion of BCR-ABL1 messenger RNA (mRNA) may be
similar between the two groups, the level of genomic
BCR-ABL1 DNA is higher in e13a2 groups [26]. This
may suggest that imatinib may be effective in reducing
mRNA expression in both groups but less effective at
reducing leukaemic cell burden in the e13a2 group. This
may then underpin some of the differences we have ob-
served when comparing deep molecular responses.
As OS and EFS were very similar between the two
groups there is little evidence to suggest that in the
current real world patient population that the type of
transcript will ultimately affect the disease course. This,
it could be argued, renders all of the above discussion as
largely academic. However, we would suggest that given
the critical need to obtain adequate deep and sustained
molecular responses to allow patients the chance of
treatment free life that there is an argument for the
choice of TKIs with increased potency in the front line
setting for younger patients with e13a2 transcripts. One
study has suggested that the molecular response to ima-
tinib in the e13a2 is inferior to that of second generation
TKIs but that this was not seen in the e14a2 group [23].
Ideally, whether this front line use of second generation
TKIs in this group will overcome some of the observed
differences should be tested in a prospective study and
may need to be offset against the greater toxicities of
these agents. Ultimately this may help physician and pa-
tient make more informed decisions at diagnosis and
allow for a more personalised approach to initial ther-
apy. We did observe blast crisis only in the e14a2 group
and the need for allogeneic stem cell transplantation
only in the e14a2 group which appears contradictory to
the other findings. Given the higher number of e14a2
patients neither of these were of statistical significance.
One study had suggested a higher rate of blast crisis
transformation in the e13a2 group [27].
Conclusion
Our own approach over the past seven years has been
homogenous with regards to front line therapy. With the
Greenfield et al. BMC Hematology            (2019) 19:7 Page 8 of 9critical importance of obtaining optimal early response
to TKI therapy in allowing patients to attempt and
sustain a treatment free remission, early personalised de-
cisions regarding therapy may help to optimise treat-
ment. Our results are in keeping with other published
series in suggesting an inferior response in patients with
an e13a2 transcript type. Prospective studies evaluating
alternative TKI use in this group as up front therapy
may overcome these findings in real world population
studies may help to guide physician and patient decision
making at the outset.
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